Biostage (NASDAQ: BSTG) is a biotech company in the emerging field of regenerative medicine. The company’s goal is to regenerate and restore organ function of the esophagus, trachea or bronchus damaged by cancer, trauma, infection or congenital diseases. Using its Cellframe technology, Biostage has been developing a new generation of organ implants capable of being used in the esophagus and main airways (trachea and bronchi). The company is expanding its preclinical data in collaboration with the Mayo Clinic and intends to submit an IND with the FDA for its first indication in 2016. For more information, visit the company’s website at www.biostage.com